Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CXCR4 was upregulated in lung cancer tissues and cells, which promoted lung cancer cells to migrate and invade.
|
31287095 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The positive rate of CD68 was 66.2% (45/68) and CXCR4 was 61.8% (42/68) in the lung cancer tissues, while the rates in normal tissues were statistically significantly lower at 27.3% (3/17) and 11.8% (2/17), respectively.
|
29745083 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the challenges and potential benefits of incorporating drugs that target CXCL12/CXCR4 into immune-based lung cancer therapeutic protocols are discussed.
|
30257500 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrated that miR-1246 inhibited cell invasion and EMT process by targeting CXCR4 and blocking JAK/STAT and PI3K/AKT signal pathways in lung cancer cells.
|
29171984 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, CXCR4 promoted lung cancer-induced osteoclast differentiation with increased osteoclast formation.
|
30355915 |
2018 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Neither of these dosing strategies prevented murine lung cancer; however, we did detect changes in pulmonary inflammatory cell infiltrate and expression of CXCR4 (a chemokine receptor previously shown to increase in response to treprostinil exposure) in tumor-bearing, treprostinil-treated animals, indicating that the drug was bioavailable.
|
28851689 |
2017 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The effects of overexpression of CXCR4 on lung cancer cell functions were investigated by migration and invasion assays.
|
29344197 |
2017 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CXCR4 and VEGF-C mRNA expression were observed in 78 (70.9%) and 64 (58.2%) lung cancer tissues, while CXCR4 and VEGF-C protein expression were observed in 76 (69.9%) and 58 (52.7%) lung cancer tissues, respectively.
|
28925100 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings provide novel evidence that OGT functions in metastatic spread of HPV E6/E7-positive tumor cells to the lungs through E6/E7, HCF-1 and CXCR4, suggesting OGT might be a therapeutic target for HPV-positive lung cancer.
|
27845045 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate miR-410 increases the levels of stem cells marker Sox2, Oct4, Nanog, CXCR4 as well as lung cancer stem cells surface marker CD44 and CD166.
|
28076327 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirdly, we detected that SDF-1 facilitated lung cancer cell proliferation and drug resistance via the CXCR4-mediated signaling pathway which involved NF-κB and Bcl-xL.
|
27035564 |
2016 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ectopic expression of EGFR-L858R in lung cancer cells acted through activation of ERK signaling pathways to induce the expression of CXCR4.
|
26338423 |
2015 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, microenvironment stimuli eliciting epithelial-to-mesenchymal transition, including signals from cancer-associated fibroblasts, are able to increase the dissemination potential of lung cancer cells through the generation of the CD133(+)/CXCR4(+)/EpCAM(-) subset.
|
26141860 |
2015 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Endogenous CXCR4 protein expression levels varied among the four human lung cancer cell lines.
|
25775124 |
2015 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore investigated whether targeting HuR using a siRNA-based nanoparticle plus AMD3100 would suppress CXCR4 and inhibit lung cancer metastasis.
|
26494555 |
2015 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression analysis revealed that higher odds ratios (ORs) for lung cancer were seen for individuals with CXCL12/SDF1 AA (an OR of 1.95, 95% CI 1.08-3.50, p=0.018), or CXCR4 TT (an OR of 4.71, 95% CI 1.99-11.2, p<0.0001), and for individuals with both CXCL12/SDF1 AA and CXCR4 TT genotypes (an OR of 12.4, 95% CI 1.56-98.3, p=0.002).
|
21292343 |
2011 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further understanding of the CXCR4/CXCL12 pathway in SCLC and NSCLC may provide a rationale for innovative research on the CXCR4 receptor as a potential novel therapeutic target in lung cancer.
|
20147779 |
2010 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcriptase-polymerase chain reaction and flow cytometry studies demonstrated SDF-1 receptor (CXCR4) messenger RNA (mRNA) and surface expression of CXCR4 in lung cancer cell lines, especially higher in those with high invasiveness (A549) as compared with lower level in H928 cells and H1299 cells.
|
17916907 |
2008 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
From these data, the CRAd-CXCR4.RGD appears to be a promising novel CRAd agent for lung cancer targeting with low host toxicity.
|
17113184 |
2007 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, s.c. inoculation of lung cancer cells with low expression of CXCR4 in nude mice showed 0- to 2-fold decrease in lung metastatic foci than that with high expression of CXCR4.
|
16322285 |
2005 |